ClinicalTrials.Veeva

Menu

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Pantoprazole 80 mg in Healthy Subjects

Sanofi logo

Sanofi

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: Placebo
Drug: Clopidogrel
Drug: Pantoprazole

Study type

Interventional

Funder types

Industry

Identifiers

NCT01129427
INT11374

Details and patient eligibility

About

Primary objective:

  • Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given concomitantly with pantoprazole 80 mg/day compared to given alone in healthy male subjects
  • Compare the pharmacokinetic profiles of clopidogrel active metabolite when clopidogrel is given either alone or concomitantly with pantoprazole

Secondary Objective:

  • Compare the pharmacokinetic profiles of clopidogrel when clopidogrel is given either alone or concomitantly with pantoprazole

Full description

The total study duration per subjects is 8 - 9 weeks broken down as follows:

  • Screening: 2 to 21 days before the first dosing
  • Period clopidogrel/placebo: 7 days including 5 days treatment
  • Period clopidogrel/placebo + pantoprazole: 14 days including 12 days treatment
  • Washout between periods: at least 14 days after last dosing with respect to clopidogrel treatment
  • End of study: 7 to 10 days after the last dosing

Enrollment

66 patients

Sex

Male

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy male subject:

  • as determined by medical history, physical examination including vital signs and clinical laboratory tests:
  • with a body weight between 50 kg and 95 kg and with a Body Mass Index (BMI) between 18 and 30 kg/m²

Exclusion criteria

  • Evidence of inherited disorder of coagulation/hemostasis functions
  • Smoking more than 5 cigarettes or equivalent per day
  • Abnormal hemostasis screen
  • Unability to abstain from intake of any drug affecting hemostasis throughout the whole study duration
  • Any contraindication to clopidogrel and/or pantoprazole

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

66 participants in 4 patient groups, including a placebo group

Group clopidogrel - clopidogrel + pantoprazole
Experimental group
Description:
Period 1: * Day 1: clopidogrel 300 mg loading dose * Day 2 to Day 5: clopidogrel 75 mg, once daily Period 2: * Day -7 to Day -1: pantoprazole 80 mg, once daily * Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly * Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily Each intake is under fasted conditions.
Treatment:
Drug: Pantoprazole
Drug: Clopidogrel
Group placebo - placebo + pantoprazole
Placebo Comparator group
Description:
Period 1: * Day 1: placebo loading dose * Day 2 to Day 5: placebo, once daily Period 2: * Day -7 to Day -1: pantoprazole 80 mg, once daily * Day 1: placebo loading dose + pantoprazole 80 mg concomitantly * Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily Each intake is under fasted conditions.
Treatment:
Drug: Pantoprazole
Drug: Placebo
Group clopidogrel + pantoprazole - clopidogrel
Experimental group
Description:
Period 1: * Day -7 to Day -1: pantoprazole 80 mg, once daily * Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly * Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily Period 2: * Day 1: clopidogrel 300 mg loading dose * Day 2 to Day 5: clopidogrel 75 mg, once daily Each intake is under fasted conditions.
Treatment:
Drug: Pantoprazole
Drug: Clopidogrel
Group placebo + pantoprazole placebo
Placebo Comparator group
Description:
Period 1: * Day -7 to Day -1: pantoprazole 80 mg, once daily * Day 1: placebo loading dose + pantoprazole 80 mg concomitantly * Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily Period 2: * Day 1: placebo loading dose * Day 2 to Day 5: placebo, once daily Each intake is under fasted conditions.
Treatment:
Drug: Pantoprazole
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems